The report "North
American Drug Delivery Technologies Market by Route of Administration
(Oral (Solid), Pulmonary (Nebulizer), Injectable (Device), Ocular (Device),
Nasal (Drop), Topical (Solid), Implantable (Active)), End User (Hospital, Home
Care) - Global Forecast to 2021 The North American drug
delivery technologies market is projected to reach USD 758.7 Billion by 2021
from USD 520.0 Billion in 2016, at a CAGR of 6.5%.
Browse 206
market data Tables and 57 Figures spread through 275 Pages and in-depth TOC on "North American Drug Delivery
Technologies Market “
Early buyers will receive 10%
customization on This report.
Factors such as rising
prevalence of chronic diseases, growth in the biologics market, funding
initiatives for drug delivery research, and technological advancements are
driving the growth of this market. However, risk of needlestick injuries and
side effects related to drugs are expected to restrain the growth of this
market in the coming years.
Based on the route of administration,
the North American drug delivery technologies market is segmented into oral,
pulmonary, injectable, ocular, nasal, topical, implantable, and transmucosal
drug delivery. The topical drug delivery market is expected to grow at the
highest CAGR during the forecast period. The high growth in this segment is
attributed to the advantages of topical drugs, such as convenience and ease of
use, right dosage to the right place, painless application, noninvasive nature,
superior spreadability, and enhanced patient compliance.
On the basis of type, the oral drug
delivery technologies market is segmented into solid, liquid, and semi-solid
drug delivery. Solid oral drug delivery is segmented into tablets, capsules,
pills, and powders. In 2016, tablets are estimated to account for the largest
share of the solid oral drug delivery market. High patient compliance and
acceptability are the major factors driving the growth of this market segment.
The injectable drug delivery market is
segmented into two broad categories, namely, devices and formulations. Devices
are further subsegmented into conventional and self-injectors, while
formulations are further categorized into conventional, novel, and long-acting.
In 2016, novel drug delivery formulations are expected to account for the
largest share of the formulations market. Enhanced efficacy, increased patient
compliance by decreasing dose frequency, and targeted drug delivery (which
reduces side effects) are some of the key factors driving the growth of this
market segment.
Topical drug delivery is segmented into
solid, liquid, semi-solid, and transdermal drug delivery. Transdermal drug
delivery is expected to register the highest CAGR during the forecast period.
The noninvasive nature of this drug delivery system, feasibility of
self-administration, and improved patient compliance are the major factors
driving the growth of the transdermal drug delivery market.
The Sample Report For This
Report@
The North American drug delivery technologies
market is segmented on the basis of route of administration, end user, and
country. The U.S. market is expected to dominate the North American drug
delivery technologies market in 2016 and is projected to grow at the highest
CAGR during the forecast period. The large share of the U.S. in the North
American market can primarily be attributed to factors such as the rising
prevalence of chronic diseases, rapidly growing geriatric population, growth in
the biologics market, and growing regulatory approvals and new product
launches.
Prominent players in this market
include Johnson & Johnson, Inc. (U.S.), Merck & Co. Inc. (U.S.),
Novartis AG (Switzerland), Bayer AG (Germany), 3M Company (U.S.), F.
Hoffmann-La Roche (Switzerland), Becton, Dickinson and Company (U.S.),
GlaxoSmithKline (U.K.), Pfizer, Inc. (U.S.), Antares Pharma (U.S.), and Sanofi
(France).
Get The PDF
Brochure For This Report@
About MarketsandMarkets™:
MarketsandMarkets™
provides quantified B2B research on 30,000 high growth niche
opportunities/threats which will impact 70% to 80% of worldwide companies’
revenues. Currently servicing 5000 customers worldwide including 80% of global
Fortune 1000 companies as clients. Almost 75,000 top officers across eight
industries worldwide approach MarketsandMarkets™ for their painpoints around
revenues decisions.
Our 850
fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth
markets following the "Growth Engagement Model – GEM". The GEM aims
at proactive collaboration with the clients to identify new opportunities,
identify most important customers, write "Attack, avoid and defend"
strategies, identify sources of incremental revenues for both the company and
its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants
(Positioning top players across leaders, emerging companies, innovators,
strategic players) annually in high growth emerging segments.
MarketsandMarkets™ is determined to benefit more than 10,000 companies this
year for their revenue planning and help them take their
innovations/disruptions early to the market by providing them research ahead of
the curve.
MarketsandMarkets’s
flagship competitive intelligence and market research platform, "RT"
connects over 200,000 markets and entire value chains for deeper understanding
of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Rohan
MarketsandMarkets™
701
Pike Street
Suite
2175, Seattle,
WA
98101, United States
Tel:
1-888-600-6441
No comments:
Post a Comment